Drugs / UB_TT170
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05312411 | May 2022 → Mar 2025 overdue | osteosarcoma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB_TT170 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05312411 ↗ |
| Modality | Small molecule | “Bispecific small molecule adapter formulated with phosphate buffered saline” NCT05312411 ↗ |
| Route | Other | “infusions of UB-TT170” NCT05312411 ↗ |